Merck expands F-star collaboration to include immuno-oncology assets

Merck has announced a new immuno-oncology-focused strategic collaboration project with the Cambridge-based biopharmaceutical company F-star.

The companies will work together on the development and commercialisation of five bispecific immuno-oncology antibodies, with Merck also gaining further rights to replace or add to these antibodies using F-star's bispecific antibody platform.

Upon delivery of pre-defined data packages, Merck has the option to acquire five of F-star's bispecific programmes, including F-star's preclinical lead asset FS118, which is designed to block LAG-3 and PD-L1.

Merck will pay up to 115 million euros (100.39 million pounds) in upfront fees, research funding and milestone payments in the first two years, with further payments contingent upon exercising its purchasing options.

Luciano Rossetti, executive vice-president and global head of research and development at the biopharma business of Merck, said: "This deal complements our internal capabilities in immuno-oncology and positions us as a potential leader in this important area of research."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.